TTR Gene Editing Compositions and Methods for Treating ATTR Amyloidosis

The EPO granted patent EP3688161A1 to Intellia Therapeutics covering CRISPR-based gene editing compositions targeting the TTR gene for treatment of ATTR amyloidosis. The patent claims涵盖 guide RNA structures, donor templates for homology-directed repair, and lipid nanoparticle delivery formulations. Designated states include all 38 EPO member countries, providing broad geographic coverage across Europe.

For pharmaceutical companies and biotech firms developing gene therapies for transthyretin amyloidosis, this patent creates potential licensing obligations or may necessitate design-around strategies. Competitors in the ATTR therapeutic space should assess whether their development programs might infringe these claims. The patent reinforces Intellia's IP position in CRISPR-mediated in vivo gene editing for rare disease applications.